Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

All Issues

Molecular pathology selected abstracts

July 2026—Parkinson’s disease, which is characterized by loss of dopamine-producing neurons in the brain’s substantia nigra and the pathologic misfolding and accumulation of alpha-synuclein, can result in a range of motor and nonmotor symptoms that may vary by individual. The cardinal motor symptoms of Parkinson’s disease (PD) are bradykinesia (slowness of movement), resting tremor, rigidity, and postural instability. A prodromal phase of the disease can generate nonmotor symptoms, such as a reduced sense of smell years prior to the onset of cardinal motor symptoms.

Pathology informatics selected abstracts

July 2026—Apollo is a health care-scale multimodal foundation model designed to integrate longitudinal clinical data into unified virtual patient representations. It was developed by the authors using data from a major U.S. health care system and trained on approximately 25 billion clinical records from 7.2 million patients that spanned more than three decades. The data set incorporated 12 medical specialties and 28 clinical modalities, including pathology images, laboratory testing, clinical documentation, medications, and structured electronic health record data.

Q&A column

July 2026
Q. What is the recommended approach for determining the HIV status of patients who are taking HIV pre-exposure prophylaxis or have received oral PrEP within the past three months or intramuscular PrEP within the past 12 months? Read answer.
Q. Our providers pointed out that lipoprotein(a) results from different laboratories are discordant, so they asked us to bring the assay in-house. Is this a good idea? Read answer.

Newsbytes

July 2026—Dedicated training in histology is increasingly getting short shrift as many academic medical institutions nationwide move to an organ system-based teaching structure. Recognizing this trend, a group of faculty and residents at the University of Wisconsin School of Medicine and Public Health are employing creativity, a simple software program, and a bit of teamwork to boost medical students’ exposure to the specialty.

Letters

July 2026—The volume of information pathology residents need to know by the end of residency to pass the board exams is extraordinarily large. Certain subspecialties within pathology such as hematopathology can be especially challenging because there are hundreds of CD markers, which can make memorizing them and their associated diseases difficult. Articles have been published on the overload and stress pathology trainees feel.

Put It on the Board

July 2026—The renewed restriction on remote participation in cytology workflows could have unintended consequences for access to and efficiency and continuity of care, write authors of a Correspondence published online in May in Nature Medicine.

Early days for menin inhibitor monitoring

June 2026—In the cat-and-mouse maneuverings that often propel new cancer treatments, menin inhibitors are proving to be successful epigenetic therapies for acute leukemia. Last November brought FDA approval of revumenib for treatment of adults and children (one year and older) with relapsed or refractory acute myeloid leukemia with NPM1 gene mutations.

IHC workup of lung neuroendocrine neoplasms

June 2026—The immunostaining landscape for lung neuroendocrine tumors continues to evolve, and Humberto Trejo Bittar, MD, in a CAP25 lung cancer session last fall, captured where it stands.

Lab leaders weigh alternative revenue models

June 2026—Alternative revenue models for laboratories, specifically laboratory testing for functional health and other health care practices that traditionally haven’t been part of conventional medicine, came up in a May 6 online Compass Group roundtable, led by CAP TODAY publisher Bob McGonnagle.

MARKETPLACE

TRENDING